J
John T. Horan
Researcher at Emory University
Publications - 106
Citations - 3637
John T. Horan is an academic researcher from Emory University. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 29, co-authored 93 publications receiving 3107 citations. Previous affiliations of John T. Horan include University of Rochester & Children's Hospital Oakland Research Institute.
Papers
More filters
Journal ArticleDOI
The genetic basis and cell of origin of mixed phenotype acute leukaemia
Thomas B. Alexander,Thomas B. Alexander,Zhaohui Gu,Ilaria Iacobucci,Kirsten Dickerson,John K. Choi,Beisi Xu,Debbie Payne-Turner,Hiroki Yoshihara,Mignon L. Loh,John T. Horan,Barbara Buldini,Giuseppe Basso,Sarah Elitzur,Valerie de Haas,C. Michel Zwaan,Allen Eng Juh Yeoh,Dirk Reinhardt,Daisuke Tomizawa,Nobutaka Kiyokawa,Tim Lammens,Barbara De Moerloose,Daniel Catchpoole,Hiroki Hori,Anthony V. Moorman,Andrew S. Moore,Ondrej Hrusak,Soheil Meshinchi,Soheil Meshinchi,Etan Orgel,Meenakshi Devidas,Michael J. Borowitz,Brent L. Wood,Nyla A. Heerema,Andrew Carrol,Yung-Li Yang,Malcolm A. Smith,Tanja M. Davidsen,Leandro C. Hermida,Patee Gesuwan,Marco A. Marra,Yussanne Ma,Andrew J. Mungall,Richard A. Moore,Steven J.M. Jones,Marcus B. Valentine,Laura J. Janke,Jeffrey E. Rubnitz,Ching-Hon Pui,Liang Ding,Yu Liu,Jinghui Zhang,Kim E. Nichols,James R. Downing,Xueyuan Cao,Lei Shi,Stanley Pounds,Scott Newman,Deqing Pei,Jaime M. Guidry Auvil,Daniela S. Gerhard,Stephen P. Hunger,Hiroto Inaba,Charles G. Mullighan +63 more
TL;DR: A large-scale genomics study shows that the cell of origin and founding mutations determine disease subtype and lead to the expression of multiple haematopoietic lineage-defining antigens in mixed phenotype acute leukaemia.
Journal ArticleDOI
HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.
Ann E. Woolfrey,John P. Klein,Michael Haagenson,Stephen R. Spellman,Effie W. Petersdorf,Machteld Oudshoorn,James Gajewski,Gregory A. Hale,John T. Horan,Minoo Battiwalla,Susana R. Marino,Michelle Setterholm,Olle Ringdén,Carolyn Katovich Hurley,Neal Flomenberg,Claudio Anasetti,Marcelo Fernandez-Vina,Stephanie J. Lee +17 more
TL;DR: HLA-C antigen-mismatched unrelated PBSC donors were associated with worse outcomes compared with 8/8 HLA-matched donors, and HLA mismatch was not associated with relapse or chronic GVHD.
Journal ArticleDOI
A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing Sibling Allografting for Acute Lymphoblastic Leukemia in First or Second Complete Remission
David I. Marks,Stephen J. Forman,Karl G. Blume,Waleska S. Pérez,Daniel J. Weisdorf,Armand Keating,Robert Peter Gale,Mitchell S. Cairo,Edward A. Copelan,John T. Horan,Hillard M. Lazarus,Mark R. Litzow,Philip L. McCarthy,Kirk R. Schultz,David D. Smith,Michael E. Trigg,Mei-Jie Zhang,Mary M. Horowitz +17 more
TL;DR: For HLA-identical sibling allografts for acute lymphoblastic leukemia in CR2, there is an advantage in substituting etoposide for Cy or, when Cy is used, in increasing the TBI dose to > or =13 Gy.
Journal ArticleDOI
Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigen–Identical Sibling Transplants for Adults With Leukemia
Theresa Hahn,Philip L. McCarthy,Mei-Jie Zhang,Dan Wang,Mukta Arora,Haydar Frangoul,Robert Peter Gale,Gregory A. Hale,John T. Horan,Luis Isola,Richard T. Maziarz,Jon J. van Rood,Vikas Gupta,Joerg Halter,Vijay Reddy,Pierre Tiberghien,Mark R. Litzow,Claudio Anasetti,Stephen Pavletic,Olle Ringdén +19 more
TL;DR: This analysis confirmed several previously reported risk factors for grade 2 to 4 acute GVHD and identified several new factors that may facilitate individualized risk estimates and raise several interesting biologic questions.
Journal ArticleDOI
Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?
John T. Horan,Brent R. Logan,Manza A. Agovi-Johnson,Hillard M. Lazarus,Andrea Bacigalupo,Karen K. Ballen,Christopher Bredeson,Matthew Carabasi,Vikas Gupta,Gregory A. Hale,Hanna Jean Khoury,Mark B. Juckett,Mark R. Litzow,Rodrigo Martino,Philip L. McCarthy,Franklin O. Smith,J. Douglas Rizzo,Marcelo C. Pasquini +17 more
TL;DR: The results suggest that innovations in transplantation care since the 1980s and 1990s have reduced the risk of TRM in patients undergoing allogeneic HCT for AML and that this reduction has been accompanied by improvements in overall survival.